AUCATZYL® (obecabtagene autoleucel) net product revenue of $23.3 million* for the fourth quarter of 2025 and $74.3 million* for the full year of ...
AUCATZYL (obecabtagene autoleucel) net product revenue of $23.3 million* for the fourth quarter of 2025 and $74.3 million* for the full year of 2025AUCATZYL UK launch underway following successful Nat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results